End	O
Points	O

The	O
primary	O
end	O
point	O
was	O
viral	B-PrimaryOutcome
clearance	I-PrimaryOutcome
rate	I-PrimaryOutcome
at	B-TimeFrame
day	I-TimeFrame
7	I-TimeFrame
after	I-TimeFrame
randomization	I-TimeFrame
.	O

After	O
randomization	O
,	O
respiratory	O
samples	O
were	O
collected	O
every	O
1	O
–	O
2	O
days	O
until	O
viral	O
clearance	O
.	O

Viral	O
clearance	O
was	O
defined	O
as	O
reverse	B-OutcomeDefinition
transcriptase	I-OutcomeDefinition
polymerase	I-OutcomeDefinition
chain	I-OutcomeDefinition
reaction	I-OutcomeDefinition
(	I-OutcomeDefinition
RT	I-OutcomeDefinition
-	I-OutcomeDefinition
PCR	I-OutcomeDefinition
)	I-OutcomeDefinition
negative	I-OutcomeDefinition
on	I-OutcomeDefinition
at	I-OutcomeDefinition
least	I-OutcomeDefinition
2	I-OutcomeDefinition
consecutive	I-OutcomeDefinition
oropharyngeal	I-OutcomeDefinition
swabs	I-OutcomeDefinition
collected	I-OutcomeDefinition
at	I-OutcomeDefinition
least	I-OutcomeDefinition
1	I-OutcomeDefinition
–	I-OutcomeDefinition
2	I-OutcomeDefinition
days	I-OutcomeDefinition
apart	I-OutcomeDefinition
.	O

Secondary	O
end	O
points	O
included	O
viral	B-SecondaryOutcome
clearance	I-SecondaryOutcome
at	B-TimeFrame
day	I-TimeFrame
3	I-TimeFrame
and	I-TimeFrame
day	I-TimeFrame
5	I-TimeFrame
,	O
the	O
critical	B-PrimaryOutcome
illness	I-PrimaryOutcome
rate	I-PrimaryOutcome
of	I-PrimaryOutcome
subjects	I-PrimaryOutcome
during	B-TimeFrame
the	I-TimeFrame
14	I-TimeFrame
days	I-TimeFrame
after	I-TimeFrame
randomization	I-TimeFrame
,	O
the	B-SecondaryOutcome
mortality	I-SecondaryOutcome
rate	I-SecondaryOutcome
of	I-SecondaryOutcome
subjects	I-SecondaryOutcome
at	B-TimeFrame
day	I-TimeFrame
14	I-TimeFrame
,	O
and	O
the	B-SecondaryOutcome
number	I-SecondaryOutcome
of	I-SecondaryOutcome
participants	I-SecondaryOutcome
with	I-SecondaryOutcome
treatment	I-SecondaryOutcome
-	I-SecondaryOutcome
related	I-SecondaryOutcome
adverse	I-SecondaryOutcome
events	I-SecondaryOutcome
.	O

